Embolic stroke of undetermined source

And so I think it's actually a largely generalizable study, especially given the very positive efficacy and safety findings.

I think that study has given us new knowledge about the pathophysiology and the involvement of factor XI in the pathophysiology of strokes of different subtypes, because I don't think I would have expected that it would work in lacunar strokes or in ESUS where the DOACs compared with aspirin were not beneficial.

So I think we've learned a lot.

And as you said, Mike, when you looked at the inclusion criteria, it was almost every subtype of non-cardioembolic stroke, which makes it generalizable to the vast majority of patients.